Granted Patent
B2
US 9,845,332 · App. 15/599,769 · Granted Dec 19, 2017
Neprilysin inhibitors
Inventors:
Roland Gendron (El Verano, CA); Melissa Fleury (Brisbane, CA); Adam D. Hughes (Half Moon Bay, CA)
Assignee:
THERAVANCE BIOPHARMA R&D IP, LLC
C07D498/08A61K31/42A61K31/422A61K31/5377A61K45/06C07D207/34C07D213/79C07D213/80C07D213/81C07D231/14C07D233/26C07D233/90C07D237/04C07D237/24C07D239/34C07D239/36C07D241/24C07D249/04C07D249/08C07D249/10C07D249/12C07D249/18C07D257/04C07D261/12C07D261/18C07D261/20C07D263/34C07D263/56C07D271/06C07D277/46C07D277/56C07D307/68C07D333/40C07D333/70C07D401/04C07D401/06C07D403/04C07D403/06C07D405/12C07D409/06C07D413/04C07D413/06C07D413/12C07D471/04C07D498/04
View Patent ↗
Loading inventors, assignments & file history…
Abstract
In one aspect, the invention relates to compounds having the formula: where R 1 -R 6 , a, b, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.
Claims (1)
1. (2R,4R)-5-Biphenyl-4-yl-2-hydroxy-4-[(1-hydroxy-1H-[1,2,3]triazole-4-carbonyl)-amino]-pentanoic acid or a pharmaceutically acceptable salt thereof.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Apr 28, 2026
From: THERAVANCE BIOPHARMA R&D IP, LLC
To: EONHF, INC.
Reel/Frame 075494/0756 →
Continuity (6)
Provisional Application
61423180
· Dec 15, 2010